Bicycle Therapeutics (BCYC) Insider Trading & Ownership $20.36 -0.12 (-0.59%) (As of 11/20/2024 ET) Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Bicycle Therapeutics (NASDAQ:BCYC) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage8.50%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)6Amount OfInsider Selling(Last 12 Months)$683,852.68 Get BCYC Insider Trade Alerts Want to know when executives and insiders are buying or selling Bicycle Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address BCYC Insider Buying and Selling by Quarter Ad Crypto Swap Profits[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.Register for the FREE Workshop Now & get $10 in Bitcoin Bicycle Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails11/11/2024Travis Alvin ThompsonCAOSell6,256$25.11$157,088.16 10/3/2024Kevin LeeCEOSell3,212$22.26$71,499.12 10/3/2024Michael Charles Ferguso HannayInsiderSell247$22.26$5,498.22 10/3/2024Michael SkynnerCTOSell972$22.26$21,636.72 10/3/2024Travis Alvin ThompsonCAOSell153$22.26$3,405.78 7/3/2024Kevin LeeCEOSell3,194$19.64$62,730.16 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 7/3/2024Michael Charles Ferguso HannayInsiderSell246$19.64$4,831.44 7/3/2024Michael SkynnerCTOSell967$19.64$18,991.88 7/3/2024Travis Alvin ThompsonCAOSell148$19.64$2,906.72 4/11/2024Michael Charles Ferguso HannayInsiderSell257$22.49$5,779.93 4/3/2024Kevin LeeCEOSell3,158$23.81$75,191.98 4/3/2024Michael SkynnerCTOSell955$23.81$22,738.55 4/3/2024Nicholas KeenInsiderSell790$23.81$18,809.90 4/3/2024Travis Alvin ThompsonCAOSell152$23.81$3,619.12 1/3/2024Kevin LeeCEOSell8,703$17.50$152,302.50 1/3/2024Nigel CrockettInsiderSell2,643$17.50$46,252.50 1/3/2024Travis Alvin ThompsonCAOSell604$17.50$10,570.00 (Data available from 1/1/2013 forward) BCYC Insider Trading Activity - Frequently Asked Questions Who is on Bicycle Therapeutics's Insider Roster? The list of insiders at Bicycle Therapeutics includes Alistair Milnes, Kevin Lee, Lee Kalowski, Michael Charles Ferguso Hannay, Michael Skynner, Nicholas Keen, Nigel Crockett, Pierre Legault, and Travis Alvin Thompson. Learn more on insiders at BCYC. What percentage of Bicycle Therapeutics stock is owned by insiders? 8.50% of Bicycle Therapeutics stock is owned by insiders. Learn more on BCYC's insider holdings. Which Bicycle Therapeutics insiders have been selling company stock? The following insiders have sold BCYC shares in the last 24 months: Alistair Milnes ($8,840.00), Kevin Lee ($634,453.02), Lee Kalowski ($60,681.26), Michael Charles Ferguso Hannay ($16,109.59), Michael Skynner ($84,123.42), Nicholas Keen ($39,417.59), Nigel Crockett ($98,589.56), and Travis Alvin Thompson ($180,200.88). How much insider selling is happening at Bicycle Therapeutics? Insiders have sold a total of 49,485 Bicycle Therapeutics shares in the last 24 months for a total of $1,122,415.32 sold. Bicycle Therapeutics Key ExecutivesDr. Kevin Lee M.B.A. (Age 56)Ph.D., CEO & Executive Director Compensation: $1.35MSir Gregory Paul Winter CBE (Age 73)FMedsci, FRS, HonFRCP, HonFTSE, Co-Founder & Non-Executive Director Compensation: $57.75kMs. Alethia Rene Young (Age 45)Chief Financial Officer Compensation: $581.69kDr. Santiago Arroyo M.D. (Age 64)Ph.D., Chief Development Officer Compensation: $916.98kDr. Christian HeinisScientific FounderMr. Alistair Milnes (Age 50)Chief Operating Officer Compensation: $796.09kMr. Travis ThompsonSenior VP, Chief Accounting Officer & Principal Accounting Officer3 recent tradesDr. Michael Skynner B.sc. Ph.d. (Age 55)Ph.D., Chief Technology Officer Compensation: $881.01kDr. Nicholas Keen Ph.D. (Age 56)Chief Scientific Officer Mr. Zafar QadirGeneral Counsel More Insider Trading Tools from MarketBeat Related Companies Immunic Insider Buying Pieris Pharmaceuticals Insider Buying Immunovant Insider Buying Organon & Co. Insider Buying ImmunityBio Insider Buying Rhythm Pharmaceuticals Insider Buying Apellis Pharmaceuticals Insider Buying MoonLake Immunotherapeutics Insider Buying Agios Pharmaceuticals Insider Buying Dyne Therapeutics Insider Buying Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Insiders Selling Into 3 Rallies: Investors Should Do the OppositeInsiders Bet Big on These Small Cap StocksHere’s Why Etsy Management Is Investing $1 Billion in BuybacksInsider Buying Signals Upside for These 3 StocksBig Buybacks Announced: 3 Stocks Insiders Are Banking On This page (NASDAQ:BCYC) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bicycle Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Bicycle Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
